Acadia Pharmaceutica (ACAD) 34.79 $ACAD
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.73 (+0.63), ACAD: 34.79 (+0.17), NVAX: 7.93 (+0.31), PFE: 36.24 (+0.12), ANAC: 99.06 (-0.14), EXEL: 8.23 (+0.08)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
BusinessWire - Thu Jun 16, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City.
ACAD: 34.79 (+0.17)
20.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 09, 1:42PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 20th, 2016 at $33.51. In approximately 3 weeks, Acadia Pharmaceuticals has returned 20.27% as of today's recent price of $40.30.
ACAD: 34.79 (+0.17)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 62.73 (+0.63), ACAD: 34.79 (+0.17), OPK: 9.94 (+0.07), CLDX: 4.70 (+0.06)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 8.48% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 2:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $36.48 to a high of $39.31. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $36.88 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
Acadia Pharmaceuticals Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 1:21PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.40 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $36.40 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
BusinessWire - Wed Jun 01, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m. Pacific Time in Rancho Palos Verdes, California.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals Announces NUPLAZID(TM) (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Tue May 31, 7:00AM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 34.79 (+0.17)
Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 34.79 (+0.17), BLCM: 14.26 (-0.70), CMRX: 3.94 (-0.05)
Acadia Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 5.56%
Comtex SmarTrend(R) - Tue May 17, 2:12PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $29.90 to a high of $32.72. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $30.18 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
Acadia reports 1Q loss
Automated Insights - Thu May 05, 4:44PM CDT
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Thursday reported a loss of $49.8 million in its first quarter.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
BusinessWire - Wed May 04, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time in Las Vegas.
ACAD: 34.79 (+0.17)
Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 7:22AM CDT
PHOTO CREDIT: ACADIA PHARMACEUTICALS What: Investors in ACADIA Pharmaceuticals had another great month: The central nervous system-focused biopharma's shares tacked on another 12.7%, according to data from S&P Global Market...
ACAD: 34.79 (+0.17)
Acadia Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.53%
Comtex SmarTrend(R) - Mon May 02, 12:35PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $30.58 to a high of $34.25. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $31.00 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 34.79 (+0.17)
Weekly Biotech Update from Market Exclusive Covering - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), Kempharm Inc. (NASDAQ:KMPH), Pfizer Inc. (NYSE
FE), Sarepta Therapeutics Inc (NASDAQ:SRPT), Collegium Pharmaceutical Inc. (NASDAQ:COLL),
ACCESSWIRE - Mon May 02, 7:12AM CDT
NEW YORK, NY / ACCESSWIRE / May 2, 2016 / Market Exclusive Weekly Biotech Report including:
ACAD: 34.79 (+0.17), KMPH: 4.12 (-0.17), SRPT: 22.43 (-0.19), PFE: 36.24 (+0.12), COLL: 12.65 (-0.09)
3 All-or-Nothing Stocks To Watch Closely
Tyler Crowe, Evan Niu, CFA, and Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 30, 7:02AM CDT
Image source: Pixabay . Some companies are pretty easy to understand because their entire future is predicated on one thing happening. These all-or-nothing stocks can be very lucrative investments if that one thing goes the right way for them, but...
TSLA: 226.19 (+9.41), ACAD: 34.79 (+0.17), DNR: 3.18 (-0.04)
FDA Approves ACADIA Pharmaceuticals' NUPLAZID(TM) (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Fri Apr 29, 6:17PM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 34.79 (+0.17)
Business Highlights
By The Associated Press - AP - Fri Apr 29, 5:33PM CDT
___
ACAD: 34.79 (+0.17), CVX: 105.84 (+1.07)
First drug for delusions in Parkinson's patients approved
AP - Fri Apr 29, 4:55PM CDT
WASHINGTON (AP) — Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder.
ACAD: 34.79 (+0.17)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.73 (+0.63), ACAD: 34.79 (+0.17), NVAX: 7.93 (+0.31), PFE: 36.24 (+0.12), ANAC: 99.06 (-0.14), EXEL: 8.23 (+0.08)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
BusinessWire - Thu Jun 16, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City.
ACAD: 34.79 (+0.17)
20.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 09, 1:42PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 20th, 2016 at $33.51. In approximately 3 weeks, Acadia Pharmaceuticals has returned 20.27% as of today's recent price of $40.30.
ACAD: 34.79 (+0.17)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 62.73 (+0.63), ACAD: 34.79 (+0.17), OPK: 9.94 (+0.07), CLDX: 4.70 (+0.06)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 8.48% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 2:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $36.48 to a high of $39.31. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $36.88 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
Acadia Pharmaceuticals Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 1:21PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.40 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $36.40 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
BusinessWire - Wed Jun 01, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m. Pacific Time in Rancho Palos Verdes, California.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals Announces NUPLAZID(TM) (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Tue May 31, 7:00AM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 34.79 (+0.17)
Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 34.79 (+0.17), BLCM: 14.26 (-0.70), CMRX: 3.94 (-0.05)
Acadia Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 5.56%
Comtex SmarTrend(R) - Tue May 17, 2:12PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $29.90 to a high of $32.72. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $30.18 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.79 (+0.17)
Acadia reports 1Q loss
Automated Insights - Thu May 05, 4:44PM CDT
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Thursday reported a loss of $49.8 million in its first quarter.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016.
ACAD: 34.79 (+0.17)
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
BusinessWire - Wed May 04, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time in Las Vegas.
ACAD: 34.79 (+0.17)
Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 7:22AM CDT
PHOTO CREDIT: ACADIA PHARMACEUTICALS What: Investors in ACADIA Pharmaceuticals had another great month: The central nervous system-focused biopharma's shares tacked on another 12.7%, according to data from S&P Global Market...
ACAD: 34.79 (+0.17)
Acadia Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.53%
Comtex SmarTrend(R) - Mon May 02, 12:35PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $30.58 to a high of $34.25. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $31.00 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 34.79 (+0.17)
Weekly Biotech Update from Market Exclusive Covering - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), Kempharm Inc. (NASDAQ:KMPH), Pfizer Inc. (NYSE
FE), Sarepta Therapeutics Inc (NASDAQ:SRPT), Collegium Pharmaceutical Inc. (NASDAQ:COLL), ACCESSWIRE - Mon May 02, 7:12AM CDT
NEW YORK, NY / ACCESSWIRE / May 2, 2016 / Market Exclusive Weekly Biotech Report including:
ACAD: 34.79 (+0.17), KMPH: 4.12 (-0.17), SRPT: 22.43 (-0.19), PFE: 36.24 (+0.12), COLL: 12.65 (-0.09)
3 All-or-Nothing Stocks To Watch Closely
Tyler Crowe, Evan Niu, CFA, and Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 30, 7:02AM CDT
Image source: Pixabay . Some companies are pretty easy to understand because their entire future is predicated on one thing happening. These all-or-nothing stocks can be very lucrative investments if that one thing goes the right way for them, but...
TSLA: 226.19 (+9.41), ACAD: 34.79 (+0.17), DNR: 3.18 (-0.04)
FDA Approves ACADIA Pharmaceuticals' NUPLAZID(TM) (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Fri Apr 29, 6:17PM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 34.79 (+0.17)
Business Highlights
By The Associated Press - AP - Fri Apr 29, 5:33PM CDT
___
ACAD: 34.79 (+0.17), CVX: 105.84 (+1.07)
First drug for delusions in Parkinson's patients approved
AP - Fri Apr 29, 4:55PM CDT
WASHINGTON (AP) — Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder.
ACAD: 34.79 (+0.17)
